clinical trial · NCT07140900
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen·phase1·recruiting·n = 60
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)XaluritamigDarolutamideAbiraterone
brief summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
started
Oct 7, 2025
primary completion
Mar 27, 2028
completion
Mar 30, 2030
last updated
Feb 13, 2026
official title
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol